Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 9
2006 23
2007 21
2008 20
2009 22
2010 14
2011 22
2012 23
2013 20
2014 22
2015 27
2016 22
2017 13
2018 17
2019 22
2020 32
2021 19
2022 22
2023 9

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Results by year

Filters applied: . Clear all
Page 1
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to a …
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [m …
Drugs for chronic insomnia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-205. Med Lett Drugs Ther. 2018. PMID: 30625122 Review. No abstract available.
Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis.
Kuriyama A, Honda M, Hayashino Y. Kuriyama A, et al. Sleep Med. 2014 Apr;15(4):385-92. doi: 10.1016/j.sleep.2013.11.788. Epub 2014 Feb 8. Sleep Med. 2014. PMID: 24656909 Review.
Ramelteon also was associated with improvement in LPS, SE, and TST. The only significant adverse event was somnolence. Short-term use of ramelteon was associated with improvement in some sleep parameters in patients with insomnia, but its clinical impact is s …
Ramelteon also was associated with improvement in LPS, SE, and TST. The only significant adverse event was somnolence. Short-term …
Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors.
Hatta K, Kishi Y, Wada K, Takeuchi T, Hashimoto N, Suda K, Taira T, Tsuchida K, Ohmori T, Akizuki N, Nishio Y, Nakanishi Y, Usui C, Kurata A, Horikawa N, Eguchi H, Ito S, Muto H, Nakamura H, Uchimura N. Hatta K, et al. J Clin Psychiatry. 2019 Dec 17;81(1):19m12865. doi: 10.4088/JCP.19m12865. J Clin Psychiatry. 2019. PMID: 31851436 Free article. Clinical Trial.
OBJECTIVE: The aim of this study was to examine the effectiveness of ramelteon and suvorexant for delirium prevention in real-world practice. It explored whether ramelteon and/or suvorexant would affect delirium prevention among both patients at risk for but without …
OBJECTIVE: The aim of this study was to examine the effectiveness of ramelteon and suvorexant for delirium prevention in real-world p …
Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial.
Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group. Hatta K, et al. JAMA Psychiatry. 2014 Apr;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320. JAMA Psychiatry. 2014. PMID: 24554232 Clinical Trial.
The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for ramelteon and 5.74 (5.05-6.42) days for placebo. Comparison by log-rank test showed that the frequency of delirium was significantly lower in patients taking ramelteon …
The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for ramelteon and 5.74 (5.05-6.42) d …
Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis.
Tian Y, Qin Z, Han Y. Tian Y, et al. Psychogeriatrics. 2022 Mar;22(2):259-268. doi: 10.1111/psyg.12792. Epub 2021 Dec 8. Psychogeriatrics. 2022. PMID: 34881812 Review.
Six studies involved the use of benzodiazepines; subgroup analysis performed separately in the suvorexant alone and suvorexant with ramelteon groups indicated that when benzodiazepine was administered, suvorexant with ramelteon was effective at reducing the i …
Six studies involved the use of benzodiazepines; subgroup analysis performed separately in the suvorexant alone and suvorexant with …
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.
Atkin T, Comai S, Gobbi G. Atkin T, et al. Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Pharmacol Rev. 2018. PMID: 29487083 Review.
The pharmacology and mechanism of action of these treatments and the evidence-base for the use of these drugs in clinical practice is outlined along with novel pipelines. There is evidence to recommend suvorexant and low-dose doxepin for sleep maintenance insomnia; there i …
The pharmacology and mechanism of action of these treatments and the evidence-base for the use of these drugs in clinical practice is …
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. Liu J, et al. Annu Rev Pharmacol Toxicol. 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23. Annu Rev Pharmacol Toxicol. 2016. PMID: 26514204 Free PMC article. Review.
This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin) and synthetic ligands (i.e., agomelatine, ramelteon, tasimelteon), with emphasis on identifying specific therapeutic effects mediated through MT1 and MT2 re …
This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin) and synthetic ligands (i.e., a …
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Sateia MJ, et al. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470. J Clin Sleep Med. 2017. PMID: 27998379 Free PMC article.
(WEAK). We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. ...(WEAK). We suggest that clinicians use ramelteon as a treatment for sleep onset insomnia (versus no treatment) in adults. ...
(WEAK). We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults. ...(WEAK). W …
Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis.
Khaing K, Nair BR. Khaing K, et al. J Psychiatr Res. 2021 Jan;133:181-190. doi: 10.1016/j.jpsychires.2020.12.020. Epub 2020 Dec 13. J Psychiatr Res. 2021. PMID: 33348252
This systematic review and meta-analysis explores the effect of melatonin and melatonin receptor agonist, ramelteon on delirium prevention in adult hospitalized patients. METHODS: Randomized Controlled trials of melatonin/ramelteon published up to May 7, 2020 were i …
This systematic review and meta-analysis explores the effect of melatonin and melatonin receptor agonist, ramelteon on delirium preve …
334 results